MCRB Valuation

Seres Therapeutics Inc

Add to Watchlist

Advanced Chart

13.240

-1.29(-8.878%)1D

Overview
Forecast
Valuation
Earnings

MCRB Relative Valuation

MCRB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MCRB is overvalued; if below, it's undervalued.

Historical Valuation

Seres Therapeutics Inc (MCRB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 19.92 is considered Overvalued compared with the five-year average of -7.22. The fair price of Seres Therapeutics Inc (MCRB) is between 7.28 to 11.89 according to relative valuation methord. Compared to the current price of 13.72 USD , Seres Therapeutics Inc is Overvalued By 15.37%.

Relative Value

Fair Zone

7.28-11.89

Current Price：13.72

15.37%

Overvalued

-1.95

Trailing

Forward

-1.53

EV/EBITDA

Seres Therapeutics Inc. (MCRB) has a current EV/EBITDA of -1.53. The 5-year average EV/EBITDA is -7.32. The thresholds are as follows: Strongly Undervalued below -46.06, Undervalued between -46.06 and -26.69, Fairly Valued between 12.05 and -26.69, Overvalued between 12.05 and 31.42, and Strongly Overvalued above 31.42. The current Forward EV/EBITDA of -1.53 falls within the Historic Trend Line -Fairly Valued range.

-1.88

EV/EBIT

Seres Therapeutics Inc. (MCRB) has a current EV/EBIT of -1.88. The 5-year average EV/EBIT is -6.30. The thresholds are as follows: Strongly Undervalued below -21.92, Undervalued between -21.92 and -14.11, Fairly Valued between 1.50 and -14.11, Overvalued between 1.50 and 9.31, and Strongly Overvalued above 9.31. The current Forward EV/EBIT of -1.88 falls within the Historic Trend Line -Fairly Valued range.

21.60

Seres Therapeutics Inc. (MCRB) has a current PS of 21.60. The 5-year average PS is 26.29. The thresholds are as follows: Strongly Undervalued below -32.86, Undervalued between -32.86 and -3.28, Fairly Valued between 55.87 and -3.28, Overvalued between 55.87 and 85.44, and Strongly Overvalued above 85.44. The current Forward PS of 21.60 falls within the Historic Trend Line -Fairly Valued range.

-20.65

P/OCF

Seres Therapeutics Inc. (MCRB) has a current P/OCF of -20.65. The 5-year average P/OCF is -5.05. The thresholds are as follows: Strongly Undervalued below -30.76, Undervalued between -30.76 and -17.91, Fairly Valued between 7.80 and -17.91, Overvalued between 7.80 and 20.65, and Strongly Overvalued above 20.65. The current Forward P/OCF of -20.65 falls within the Undervalued range.

20.30

P/FCF

Seres Therapeutics Inc. (MCRB) has a current P/FCF of 20.30. The 5-year average P/FCF is -23.35. The thresholds are as follows: Strongly Undervalued below -127.37, Undervalued between -127.37 and -75.36, Fairly Valued between 28.67 and -75.36, Overvalued between 28.67 and 80.68, and Strongly Overvalued above 80.68. The current Forward P/FCF of 20.30 falls within the Historic Trend Line -Fairly Valued range.

Seres Therapeutics Inc (MCRB) has a current Price-to-Book (P/B) ratio of 2.51. Compared to its 3-year average P/B ratio of 7.75 , the current P/B ratio is approximately -67.56% higher. Relative to its 5-year average P/B ratio of 7.18, the current P/B ratio is about -64.98% higher. Seres Therapeutics Inc (MCRB) has a Forward Free Cash Flow (FCF) yield of approximately -74.19%. Compared to its 3-year average FCF yield of -72.58%, the current FCF yield is approximately 2.22% lower. Relative to its 5-year average FCF yield of -45.57% , the current FCF yield is about 62.79% lower.

2.51

P/B

Median3y

7.75

Median5y

7.18

-68.42

FCF Yield

Median3y

-72.58

Median5y

-45.57

Competitors Valuation Multiple

The average P/S ratio for MCRB's competitors is 33.50, providing a benchmark for relative valuation. Seres Therapeutics Inc Corp (MCRB) exhibits a P/S ratio of 21.60, which is -35.54% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MCRB.O

Seres Therapeutics Inc

Spero Therapeutics Inc

Molecular Partners AG

TuHURA Biosciences Inc

Performance Decomposition

Market capitalization of MCRB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MCRB in the past 1 year is driven by Unknown.